Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
==== Sources ==== Formaldehyde (HCHO) enters the atmosphere via primary emission and secondary formation. Primary sources of atmospheric HCHO include direct biogenic emissions from vegetation and biomass burning, and anthropogenic emissions from vehicles, industrial activities, and coal combustion. Most atmospheric HCHO is secondary, produced by radical-driven oxidation of methane (CH4) and non-methane volatile organic compounds (VOCs) rather than direct emissions. Secondary production from CH4 oxidation dominates in remote and marine environments. Oxidation of biogenic and anthropogenic VOCs is the main source of HCHO in continental regions. Vegetation emits large amounts of isoprene, which is a key natural precursor of tropospheric formaldehyde over land.
== Early life and education == Namandjé Bumpus was born in Philadelphia and raised in western Massachusetts. She became interested in chemistry at a young age, even writing to the American Chemical Society while still in elementary school to ask about the kind of careers chemists can have. She earned a B.A. in Biology from Occidental College, in Los Angeles, California, in 2003. At Occidental, she was introduced to research experiences in ecology, then she ventured into pharmacology through Charles Ross Summer Research Fellowship at the University of Michigan, during which she was mentored by Dr. Richard R. Neubig. She enjoyed the experience so much that she decided to return to the University of Michigan after graduating from Occidental College in order to pursue a PhD in pharmacology. She earned her Ph.D. in pharmacology from the University of Michigan Medical School in 2007. Her thesis research, and much of her later work, examined how drugs are processed by cytochrome P450 enzymes, (CYPs) a family of heme-containing monooxygenases, that often help make drugs more soluble, aiding with drug clearance. Bumpus performed her thesis research in the laboratory of Dr. Paul F. Hollenberg, investigating how a naturally occurring mutation in CYP2B6 affects its ability to be inactivated by compounds known the inactivate the wild-type CYP2B6. She also looked into how naturally occurring variants could impact how patients cleared the antidepressant Bupropion, and the antiviral Efavirenz.
== Further reading == Brayden DJ (November 2022). "Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials". BioDrugs. 36 (6): 687–700. doi:10.1007/s40259-022-00562-6. PMID 36282433. S2CID 253109130.</ref> Fourie A, Cheng X, Chang L, Greving C, Patrick A, Knight B, et al. (October 2023). "S1028 Characterization of a First-in-Class Oral Therapy Selectively Targeting the IL-23 Pathway". American Journal of Gastroenterology. 118 (10S): S781. doi:10.14309/01.ajg.0000953752.29003.56. Ghusn W, Gala K, Rahme SJ, Salame M, Mrad R, Abboud DM, et al. (October 2023). "S1029 Disparities in Age, Sex, Race, and Ethnicity in Clinical Trials Focused on Inflammatory Bowel Disease in the United States". American Journal of Gastroenterology. 118 (10S): S781–S782. doi:10.14309/01.ajg.0000953756.85659.9e. Rusiñol L, Carmona-Rocha E, Puig L (3 July 2023). "Psoriasis: a focus on upcoming oral formulations". Expert Opinion on Investigational Drugs. 32 (7): 583–600. doi:10.1080/13543784.2023.2242767. PMID 37507233. S2CID 260286273.
Sources: en.wikipedia.org
In May 2010, In-N-Out announced plans to open new spots into Texas, specifically within the Dallas–Fort Worth area with the first In-N-Out opening in Frisco and Allen on May 11, 2011. The chain opened its first location in Austin in December 2013. There are 18 restaurant locations in the Dallas–Fort Worth area, and four in the Austin area. These new locations in Texas required the company to build a new patty production facility and distribution center in the state, according to company vice president Carl Van Fleet. In March 2014, the company confirmed its first location in San Antonio. The fall of 2014 saw the restaurant open its 22nd Texas location in Killeen. On November 20, 2014, In-N-Out opened its first location in San Antonio followed by its first location in Waco in November 2015. In January 2017, In-N-Out announced plans to expand into Houston with multiple sites planned in the area, the first being in Stafford. In January 2015, In-N-Out opened its 300th restaurant, which was located in Anaheim, California. At the time of the opening, the company had generated $558 million in annual sales and employed nearly 18,000 in California, Nevada, Utah, Texas, and Arizona. The company opened its first location in Oregon on September 9, 2015 (the same day as Harry Snyder's birthday) in Medford. It is supplied from the Lathrop, California, distribution center completed in 2006. President Lynsi Snyder stated during the opening that they will continue to open new spots. A second Oregon location was under construction in Grants Pass during September 2017.
Laminins are a family of glycoproteins of the extracellular matrix of all animals. They are major constituents of the basement membrane, namely the basal lamina (the protein network foundation for most cells and organs). Laminins are vital to biological activity, influencing cell differentiation, migration, and adhesion. Laminins are heterotrimeric protein complexes with a high molecular mass (~400 to ~900 kDa) and possess three different chains (α, β, and γ) encoded by five, four, and three paralogous genes in humans, respectively. The laminin molecules are named according to their chain composition, e.g. laminin-511 contains α5, β1, and γ1 chains. Fourteen other chain combinations have been identified in vivo. The trimeric proteins intersect, composing a cruciform structure that is able to bind to other molecules of the extracellular matrix and cell membrane. The three short arms have an affinity for binding to other laminin molecules, conducing sheet formation. The long arm is capable of binding to cells and helps anchor organized tissue cells to the basement membrane. Laminins are integral to the structural scaffolding of almost every tissue of an organism—secreted and incorporated into cell-associated extracellular matrices. These glycoproteins are imperative to the maintenance and vitality of tissue; defective laminins can cause muscles to form improperly, leading to a form of muscular dystrophy, lethal skin blistering disease (junctional epidermolysis bullosa), and/or defects of the kidney filter (nephrotic syndrome).
isoelectronicity The phenomenon of two or more chemical species (atoms, molecules, ions, etc.) being composed of different elements but having the same number of valence electrons and the same structural arrangement (i.e. the same number of atoms with the same connectivity). Isoelectronic species typically show useful consistency and predictability in their chemical properties.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
Refrigeration between 2 and 8 degrees Celsius with protection from light is the common recommendation. Many laboratories choose frozen storage at minus 20 degrees Celsius when the material will not be used soon. Repeated temperature cycling is generally avoided.